Piling up the JNK: drug synergy through ER stress.
Hertan
Lauren M
LM
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Koumenis
Constantinos
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001578:Benzopyrans / Q000008:administration & dosage / Q000494:pharmacology*; D001897:Boronic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D000069286:Bortezomib; D004357:Drug Synergism; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000201:enzymology*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D009570:Nitriles / Q000008:administration & dosage / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction
D001578:Benzopyrans; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D009570:Nitriles; D011480:Protease Inhibitors; D011719:Pyrazines; C456800:ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; D000069286:Bortezomib; D048031:JNK Mitogen-Activated Protein Kinases